Close
CDMO Safety Testing 2026
Novotech

IBM Watson Health selects iBio to support COVID-19 vaccine candidates

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

โ€“ Access the Media Pack Now

โ€“ Book a Conference Call

โ€“ Leave Message for Us to Get Back

Related stories

Angelini Pharma Expands US Presence with Catalyst Pharmaceuticals Acquisition

Angelini Pharma has finalized a definitive agreement to acquire...

Are Glutathione Injections in NYC Worth It? A Complete Guide

When whatever you do to your skin makes it...

Fujifilm Advances Drug Discovery with New Cyclic Peptide Screening Platform

FUJIFILM Corporation has developed a new screening methodology aimed...
- Advertisement -

IBM Watson Health selected iBio to receive 18 months use of the IBM clinical development (ICD) solution at no cost.

IBM Watson Health recently began offering its clinical development solution to eligible trial sponsor organizations as part of its efforts to help support the medical community to address the COVID-19 pandemic. IBM Watson is currently working with 15 COVID-19 disease trials.

โ€œWe are deeply appreciative of IBMโ€™s vote-of-confidence, which recognizes the potential of iBioโ€™s COVID-19 vaccine development efforts from among the hundreds of organizations that applied for access to IBMโ€™s ICD solution,โ€ Tom Isett, co-chairman and CEO of iBio, said in a statement.

Mr. Isett said the IBM technology would help accelerate clinical trials of iBioโ€™s COVID-19 vaccine candidates. It also complements iBioโ€™s FastPharming Systemโ€™s core speed, quality and scale-up advantages in the development of vaccines and therapeutics.

โ€œThrough strategic collaborations like this one, we believe iBio is now poised with the tools, technology and capital necessary to compete in the fight against COVID-19,โ€ Mr. Isett added

iBio expects data from the preclinical immunization studies of its two COVID-19 vaccine candidates, IBIO-200 and IBIO-201, which are being conducted at Texas A&M University System laboratories, will be available in the third quarter of 2020.

Mary Presti, VP for life sciences with IBM Watson Health, said IBM is committed to leveraging its ICD solution to help accelerate the timelines for COVID-19 clinical trials and are enabling access to the platform, free of charge, for relevant trial sponsors.

โ€œWe are inspired by iBioโ€™s commitment, as well as all of the other leaders in the life sciences community, as they apply their expertise and ingenuity to help millions of patients worldwide,โ€ she added.

ICD is a unified, software-as-a-solution-based electronic data capture platform, designed to provide end-to-end visibility as well as patient, site, and clinical trial management capabilities. ICD is designed to help clinical trial sponsors and clinical site staff reduce the time and cost of clinical trials by centralizing and organizing information, providing 24/7 access to clinical trial data via a single URL from any web-enabled device, and providing a flexible and scalable data management platform to help design and manage clinical trials by incorporating optional clinical trial-specific features and services.

Never miss a pharmaceutical headline

The pharmaceutical industry moves fast โ€“ stay on top of it with our must - read briefings.

  • The top pharma and life sciences stories, straight to your inbox
  • The biggest news, features, interviews, and analysis
  • Dedicated coverage of the key developments driving the global pharmaceutical sector

Latest stories

Related stories

Angelini Pharma Expands US Presence with Catalyst Pharmaceuticals Acquisition

Angelini Pharma has finalized a definitive agreement to acquire...

Are Glutathione Injections in NYC Worth It? A Complete Guide

When whatever you do to your skin makes it...

Fujifilm Advances Drug Discovery with New Cyclic Peptide Screening Platform

FUJIFILM Corporation has developed a new screening methodology aimed...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

โ€“ Access theMedia Pack Now

โ€“ Book a Conference Call

โ€“ Leave Message for Us to Get Back

Translate ยป